Ablynx: Corporate Presentation (Ablynx) - Apr 11, 2014 - "ALX-0061 – compelling proof-of-concept Phase IIa results"; "Treatment showed strong efficacy and was well tolerated at all doses"; "No increase of adverse events upon extension of treatment"; "No anti-drug antibodies were detected" "
P2 data • Rheumatoid Arthritis
|